Compare Crispr Therapeutics AG (CRSP) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PulteGroup, Inc. — how do they compare? Crispr Therapeutics AG trades at $54.27 (market cap $5.17B), while PulteGroup, Inc. trades at $132.77 (market cap $24.77B). The key difference: PulteGroup, Inc. is far larger — about 4.8× Crispr Therapeutics AG's market cap, and PulteGroup, Inc. pays a 0.8% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PHM | |
|---|---|---|
Market Cap | $5.17B | $24.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $142.56 |
52-Week Low | $44.34 | $110.11 |
Enterprise Value | $3.59B | $25.19B |
Dividend Yield | — | 0.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
PulteGroup (PHM) trades at $132.90, up 2.59% today, with a bullish technical signal and support near $131. The stock shows solid fundamentals with a P/E of 13.58 and net income margin of 11.62%, though recent quarters saw mixed earnings results. The company expanded into Northwest Florida and reported a Q2 2026 EPS beat, while cash flow trends remain positive.
Outlook is cautiously optimistic with a consensus price target of $137.20 offering modest upside. Risks include housing market pressure and margin declines, but strong institutional interest and a moderate buy rating suggest resilience. The stock presents a value opportunity amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
